Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Morie Gertz

Showing results (91-100 of 111) with videos related to

Pageof 12
Sort By:
Clinical Journal of the American Society of Nephrology : CJASN|October 2, 2012
Urinary albumin excretion patterns of patients with cast nephropathy and other monoclonal gammopathy-related kidney diseasesNelson Leung, Morie Gertz, Robert A Kyle, et al.
American Journal of Hematology|March 7, 2026
Predicting Early Mortality in Newly Diagnosed AL Amyloidosis: Development and Validation of the PACE Score for Daratumumab-Treated PatientsGeorge S Mellgard, Abdul-Hamid Bazarbachi, Saurabh Zanwar, et al.
American Journal of Hematology|June 8, 2026
Determinants of Long-Term Benefit From High Dose Melphalan With Autologous Stem Cell Transplant in AL AmyloidosisMaximilian J Steinhardt, Ute Hegenbart, Tamer Hellou, et al.
Research Square|April 17, 2026
Risk of AL Amyloidosis is Associated with Degree of Free Light Chain Elevation and Duration of ExposureAngela Dispenzieri, Maximilian Steinhardt, Eli Muchtar, et al.
Blood Cancer Journal|December 31, 2025
Clinical course, risk factors and mitigating strategies for Immune effector cell-associated late onset neurotoxicities after ciltacabtagene autoleucel CAR-T in multiple myelomaKenneth J C Lim, Melinda Tan, Ricardo Parrondo, et al.
British Journal of Haematology|November 20, 2020
Implications of detecting serum monoclonal protein by MASS-fix following stem cell transplantation in multiple myelomaJithma P Abeykoon, David L Murray, Isaiah Murray, et al.
Research Square|March 27, 2026
Biomarkers of Cellular Senescence and their Association with Frailty, Clinical Outcomes, and Survival in Multiple MyelomaNadine Abdallah, Byron Smith, Thomas White, et al.
Journal of Neurology|July 31, 2022
Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year updateThomas H Brannagan, Teresa Coelho, Annabel K Wang, et al.
Cancer Research|April 9, 2009
Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemiaEsteban Braggio, Jonathan J Keats, Xavier Leleu, et al.
American Journal of Hematology|February 24, 2017
A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR-CD) for untreated low-grade non-Hodgkin lymphoma requiring therapyAllison Rosenthal, Amylou C Dueck, Stephen Ansell, et al.
Pageof 12

Showing results (91-100 of 111) with videos related to

Sort By:
Pageof 12
Clinical Journal of the American Society of Nephrology : CJASN|October 2, 2012
Urinary albumin excretion patterns of patients with cast nephropathy and other monoclonal gammopathy-related kidney diseasesNelson Leung, Morie Gertz, Robert A Kyle, et al.
American Journal of Hematology|March 7, 2026
Predicting Early Mortality in Newly Diagnosed AL Amyloidosis: Development and Validation of the PACE Score for Daratumumab-Treated PatientsGeorge S Mellgard, Abdul-Hamid Bazarbachi, Saurabh Zanwar, et al.
American Journal of Hematology|June 8, 2026
Determinants of Long-Term Benefit From High Dose Melphalan With Autologous Stem Cell Transplant in AL AmyloidosisMaximilian J Steinhardt, Ute Hegenbart, Tamer Hellou, et al.
Research Square|April 17, 2026
Risk of AL Amyloidosis is Associated with Degree of Free Light Chain Elevation and Duration of ExposureAngela Dispenzieri, Maximilian Steinhardt, Eli Muchtar, et al.
Blood Cancer Journal|December 31, 2025
Clinical course, risk factors and mitigating strategies for Immune effector cell-associated late onset neurotoxicities after ciltacabtagene autoleucel CAR-T in multiple myelomaKenneth J C Lim, Melinda Tan, Ricardo Parrondo, et al.
British Journal of Haematology|November 20, 2020
Implications of detecting serum monoclonal protein by MASS-fix following stem cell transplantation in multiple myelomaJithma P Abeykoon, David L Murray, Isaiah Murray, et al.
Research Square|March 27, 2026
Biomarkers of Cellular Senescence and their Association with Frailty, Clinical Outcomes, and Survival in Multiple MyelomaNadine Abdallah, Byron Smith, Thomas White, et al.
Journal of Neurology|July 31, 2022
Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year updateThomas H Brannagan, Teresa Coelho, Annabel K Wang, et al.
Cancer Research|April 9, 2009
Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemiaEsteban Braggio, Jonathan J Keats, Xavier Leleu, et al.
American Journal of Hematology|February 24, 2017
A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR-CD) for untreated low-grade non-Hodgkin lymphoma requiring therapyAllison Rosenthal, Amylou C Dueck, Stephen Ansell, et al.
Pageof 12